[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
June 7, 2000

Implant for Chronic Nausea

Author Affiliations

Not Available

Not Available

JAMA. 2000;283(21):2779. doi:10.1001/jama.283.21.2779-JFD00004-3-1

The FDA has approved an abdominal implant (Enterra, Medtronic Corp, Fridly, Minn) for treatment of chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology. The device consists of intramuscular stomach leads and an implantable pulse generator (IPG). The stomach leads are implanted via laparoscopy on the greater curvature of the stomach and are connected to the IPG, which is implanted in a subcutaneous pocket created in the abdomen.

First Page Preview View Large
First page PDF preview
First page PDF preview